Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease

    LEXINGTON, Mass., Nov. 7 /CNW/ -- ActivBiotics, Inc. today announced the
results of its PROVIDENCE-1 clinical trial, which evaluated the effect of
rifalazil in the treatment of intermittent claudication, associated with
peripheral arterial disease (PAD). The results demonstrated that treatment for
two months with the experimental antibiotic rifalazil did not result in a
significant improvement in walking distance, claudication onset times, or
other clinically-relevant parameters of PAD.
    The results were presented earlier today at the late breaker Scientific
Session at the American Heart Association's 2007 annual meeting in Orlando,
Florida. Michael R. Jaff, DO, FACP, FACC, Assistant Professor of Medicine,
Harvard Medical School and Medical Director, Massachusetts General Hospital
Vascular Center, Boston, Massachusetts, Chair of the trial's Steering
Committee, presented the data.
    The prospective, randomized, double-blinded international study was done
on an outpatient basis with the primary endpoint being a change in baseline
peak walking time, comparing those given rifalazil against those given a
placebo. The study enrolled 297 consenting men and women (40-80 years old)
with diagnosis of intermittent claudication due to PAD who also had high
levels of antibodies to C. pneumoniae. Researchers used treadmills and quality
of life questionnaires to chart patients' progress at various times throughout
the one-year study.
    "We are clearly disappointed with the low efficacy signal seen in
rifalazil-treated patients which was only 4% greater than placebo, a
difference which was not statistically significant. On the other hand, we are
pleased that the population demographics, low placebo response and overall low
variability in this study provided a very clear cut answer," said Steven C.
Gilman, Ph.D., Chairman and CEO of ActivBiotics.
    Chlamydia pneumoniae infection of the vascular system has long been
thought to play a role in accelerating the course of vascular disease
potentially by increasing inflammation in the arterial wall thus leading to
exacerbation of atherosclerosis, which could reduce blood supply to target
limbs and organs.
    "The conclusive data obtained from this well-powered and well-executed
study provides a compelling argument that C. pneumoniae does not play a role
in PAD that is modifiable by anti-bacterial therapy. Walking impairment in PAD
patients remains a significant unmet medical need, but anti-chlamydial therapy
does not appear to be the solution," Dr. Jaff said.

    About ActivBiotics, Inc.

    ActivBiotics, Inc. is a biopharmaceutical company focused on the
discovery, development and commercialization of therapies for the treatment of
inflammatory diseases and bacterial infections. For more information on
ActivBiotics, Inc., please visit our web site www.activbiotics.com.

    Safe Harbor Statement

    This press release may contain or incorporate by reference certain
statements that are not historical facts, including statements preceded by,
followed by or that include the words "may," "believes," "will", "expects,"
"anticipates" or the negation thereof, or similar expressions, which
constitute "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995 (the "Reform Act"). All statements
that address events, transactions or developments that are expected or
anticipated to occur in the future are forward-looking statements within the
meaning of the Reform Act. Such forward-looking statements involve risks,
uncertainties and other factors that may cause the actual performance or
achievements of ActivBiotics, Inc. to be materially different from any future
results, performance or achievements expressed or implied by such forward-
looking statements. For those statements, ActivBiotics, Inc. claims the
protection of the safe harbor for forward-looking statements contained in the
Reform Act. ActivBiotics, Inc. will not undertake and specifically declines
any obligation to publicly release the result of any revisions that may be
made to any forward-looking statements to reflect events or circumstances
after the date of such statements or to reflect the occurrence of anticipated
or unanticipated events.

For further information:

For further information: Glenn Kazo, Chief Business Officer,
+1-781-372-4864, gkazo@activbiotics.com, or Christina DiCarlo, Manager,
Corporate Communications, +1-781-372-4807, cdicarlo@activbiotics.com, both of 
ActivBiotics, Inc.; Web Site: http://www.activbiotics.com

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890